ReviewAdvances in experimental medicine and biology2025
Development of Animal Models for Preclinical Safety Studies.
Review in Advances in experimental medicine and biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A major concern in pluripotent stem cell (PSC)-based cell therapies is the incidence of tumor or cell mass consisting of immature or not fully differentiated cell mass generated from differentiation-resistant cells. These incidents could be caused by genetic abnormality or epi-genetic dysregulation ocurring during prolonged culture periods.In the case of iPSC-derived product, partial reprogramming or residual epigenetic memory would be special issues to consider. So far, we are unable to link the genetic abnormality or epigenetic dysregulation with the behavior of cells after transplantation in the microenvironment of tissue where transplanted. Therefore, a tumorigenicity test is indispensable as an in vivo safety test especially in first-in-human clinical studies. In this chapter, we discuss points to be considered in the selection of immuno-deficient rodents, number of rodents for one group for statistical analysis, doses of cells, selection of positive control cells, monitoring period and interpretation of test results, related to the design of tumorigenicity test from risk assessment perspective.
Indexed as
Identifiers
41136853What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.